190 related articles for article (PubMed ID: 33257031)
21. Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer.
Glaser A; Shi Z; Wei J; Lanman NA; Ladson-Gary S; Vickman RE; Franco OE; Crawford SE; Lilly Zheng S; Hayward SW; Isaacs WB; Helfand BT; Xu J
Eur Urol Open Sci; 2022 Sep; 43():54-61. PubMed ID: 36353071
[TBL] [Abstract][Full Text] [Related]
22. Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.
Helfand BT; Chen H; Fantus RJ; Conran CA; Brendler CB; Zheng SL; Walsh PC; Isaacs WB; Xu J
Prostate; 2018 Jun; ():. PubMed ID: 29923209
[TBL] [Abstract][Full Text] [Related]
23. Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes.
Ruan X; Huang D; Huang J; Tsu JH; Na R
J Transl Med; 2023 Jul; 21(1):446. PubMed ID: 37415201
[TBL] [Abstract][Full Text] [Related]
24. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
25. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.
Grenabo Bergdahl A; Holmberg E; Moss S; Hugosson J
Eur Urol; 2013 Nov; 64(5):703-9. PubMed ID: 23721957
[TBL] [Abstract][Full Text] [Related]
26. Family history is significantly associated with prostate cancer and its early onset in Chinese population.
Xu Y; Huang D; Wu Y; Ye D; Zhang N; Gao Y; Xu D; Na R; Xu J
Prostate; 2019 Nov; 79(15):1762-1766. PubMed ID: 31497879
[TBL] [Abstract][Full Text] [Related]
27. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
28. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
[TBL] [Abstract][Full Text] [Related]
29. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study.
Brook MN; Ní Raghallaigh H; Govindasami K; Dadaev T; Rageevakumar R; Keating D; Hussain N; Osborne A; Lophatananon A; ; Muir KR; Kote-Jarai Z; Eeles RA
Eur Urol; 2023 Mar; 83(3):257-266. PubMed ID: 36528478
[TBL] [Abstract][Full Text] [Related]
30. The association between family history of prostate cancer and development of prostate cancer among Korean population: A prospective cohort study using KoGES data.
Choi HG; Bang WJ; Jo JK; Oh CY; Shim M; Cho JS
Medicine (Baltimore); 2021 Feb; 100(7):e24757. PubMed ID: 33607822
[TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
[TBL] [Abstract][Full Text] [Related]
32. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
33. Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants.
Lv X; Li Y; Li R; Guan X; Li L; Li J; Si S; Ji X; Cao Y; Xue F
Prostate; 2022 Jun; 82(9):984-992. PubMed ID: 35403721
[TBL] [Abstract][Full Text] [Related]
34. Reliability of Ancestry-specific Prostate Cancer Genetic Risk Score in Four Racial and Ethnic Populations.
Shi Z; Zhan J; Wei J; Ladson-Gary S; Wang CH; Hulick PJ; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; ; Koelsch BL; Xu J
Eur Urol Open Sci; 2022 Nov; 45():23-30. PubMed ID: 36353656
[TBL] [Abstract][Full Text] [Related]
35. Genetic factors influencing prostate cancer risk in Norwegian men.
Chen H; Ewing CM; Zheng S; Grindedaal EM; Cooney KA; Wiley K; Djurovic S; Andreassen OA; Axcrona K; Mills IG; Xu J; Maehle L; Fosså SD; Isaacs WB
Prostate; 2018 Feb; 78(3):186-192. PubMed ID: 29181843
[TBL] [Abstract][Full Text] [Related]
36. Association Between the Body Mass Index and Prostate Cancer at Biopsy is Modified by Genetic Risk: A Cross-Sectional Analysis in China.
Zhang GM; Zhu Y; Chen HT; Han CT; Liu F; Xu JF; Ye DW
Medicine (Baltimore); 2015 Oct; 94(42):e1603. PubMed ID: 26496266
[TBL] [Abstract][Full Text] [Related]
37. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
38. Prostate Cancer Risk by BRCA2 Genomic Regions.
Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Tripathi V; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
Eur Urol; 2020 Oct; 78(4):494-497. PubMed ID: 32532514
[TBL] [Abstract][Full Text] [Related]
39. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
40. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
